Frequently Asked Questions about Novavax, Inc. (NVAX)

Name: Novavax, Inc. (NVAX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Novavax, Inc. (NVAX) do?

Accepted Answer

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one...

Question 2

Is Novavax, Inc. (NVAX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of NVAX reveals an Altman Z-Score of -2.05 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($1.12B most recent), help investors decide if NVAX fits their risk profile.

Question 3

What is the current P/E ratio for NVAX?

Accepted Answer

As of the latest trading session, Novavax, Inc. (NVAX) has a trailing P/E ratio of 2.93.

Question 4

Who is the CEO of Novavax, Inc.?

Accepted Answer

The current Chief Executive Officer of Novavax, Inc. is John Charles Jacobs.

Question 5

What was NVAX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Novavax, Inc. reported annual revenues of $1.12B (2025), $0.68B (2024), $0.56B (2023), $1.60B (2022), $0.20B (2021) respectively.

Question 6

Does NVAX pay a dividend?

Accepted Answer

Novavax, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does NVAX have?

Accepted Answer

In its latest reporting period, Novavax, Inc. generated $-0.25B in Free Cash Flow against a total debt load of $0.25B.

Question 8

What is the Price-to-Book (P/B) ratio of Novavax, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Novavax, Inc. (NVAX) is currently -10.11.

Question 9

What is the Price-to-Sales (P/S) ratio of NVAX?

Accepted Answer

Based on trailing twelve-month data, Novavax, Inc. (NVAX) trades at a Price-to-Sales (P/S) ratio of 1.16.

Question 10

What is Novavax, Inc.'s Return on Equity (ROE)?

Accepted Answer

Novavax, Inc. (NVAX) has a Return on Equity (ROE) of -546.21%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	1.2B	1.3B	-127.8M	248.8M	8.2M
2024-12	1.6B	2.2B	-623.8M	230.4M	-299.8M
2023-12	1.8B	2.5B	-716.9M	229.1M	-339.4M
2022-12	2.3B	2.9B	-634.1M	549.8M	-787.1M
2021-12	2.6B	2.9B	-351.7M	454M	-1.1B

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	1.2B	1.3B	-127.8M	248.8M	8.2M
2024-12	1.6B	2.2B	-623.8M	230.4M	-299.8M
2023-12	1.8B	2.5B	-716.9M	229.1M	-339.4M
2022-12	2.3B	2.9B	-634.1M	549.8M	-787.1M
2021-12	2.6B	2.9B	-351.7M	454M	-1.1B